Search

everythinglearnresearchcommunity

for

Search:↓

Alopecia Areata is treated with drugs and therapies to reduce inflammation and immune response.

Higher levels of nidogen1 and type IV collagen are found in basal cell carcinoma compared to normal skin.

CREB, a protein that can promote cancer traits, is controlled by β-catenin in skin cancer cells.

Higher fluence in hair removal damages hair follicles more, while lower fluence mimics natural hair regression, with long-term IPL treatments effectively reducing hair.

The document concludes that ERBB2 mutations are common in extramammary Paget disease and may respond to systemic treatments like cancer immunotherapy.

FOL-005, a hair growth promoter, acts locally on mouse skin where injected and could be a promising hair loss treatment.

Nivolumab can cause hair loss as a rare side effect.

Stem Cell Educator therapy helps regrow hair and improve life quality in alopecia areata patients.

Skin reactions from cancer treatments might predict how well the treatments work.

A woman with advanced eye cancer went into complete remission using a combination of immunotherapy and topical treatments.

Targeted anticancer therapies can cause severe side effects similar to traditional chemotherapy, but with different types.

Early intervention and tailored management can reduce skin side effects from cancer treatments.

Certain immune cells contribute to skin autoimmune diseases, and some treatments can reverse hair loss in these conditions.

Alopecia areata is caused by immune system issues, and JAK inhibitors might help treat it.

Different types of resting melanocyte stem cells have unique characteristics and vary in their potential to become other cells.

The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.

The Wnt/β-catenin pathway is important for body functions and diseases, and targeting it may treat conditions like cancer, but with safety challenges.

The review suggests that other immune cells besides CD8+ T cells may contribute to alopecia areata and that targeting regulatory cell defects could improve treatment.

Lysophospholipids like LPA and S1P are important for hair growth, immune responses, and vascular development, and could be targeted for treating diseases.

PPAR-γ helps control skin oil glands and inflammation, and its disruption can cause hair loss diseases.

RNA delivery is best for in-body use, while RNP delivery is good for outside-body use. Both methods are expected to greatly impact future treatments.

Thymic mesenchymal cells have unique gene expression that supports their specific functions in the thymus.

New treatments like nanotechnology show promise in improving skin cancer therapy.

Certain daily habits like stress, diet, and sleep can affect the severity of hair loss in alopecia areata.

New targeted immunotherapies are improving treatment for inflammatory skin diseases.

Mesenchymal stem cells may help treat hair loss by improving hair cell growth and reducing inflammation.

Vitamin D might be involved in the development of alopecia areata and could help in its treatment.

Autophagy helps keep skin healthy and may improve treatments for skin diseases.

Advancements in nanoformulations for CRISPR-Cas9 genome editing can respond to specific triggers for controlled gene editing, showing promise in treating incurable diseases, but challenges like precision and system design complexity still need to be addressed.

Blocking YAP/TAZ could be a new way to treat skin cancer.